Company: NCNA
Filing Date: 2025-04-24
Form Type: F-1
Source: 0001193125-25-092131
Chunk: 13

Company: NuCana plc
Filing Date: 2025-04-24
Form: F-1
Chunk 13
---
,383 ADSs and Series B Warrants to
purchase up to 16,049,383 ADSs. Each ADS, or Pre-Funded Warrant in lieu thereof, is being sold together with a Series A Warrant to purchase one ADS and a Series B Warrant to purchase one ADS. The ADSs, or Pre-Funded Warrants in lieu thereof, and the
Warrants are immediately separable and will be issued separately, but must be purchased together. The assumed combined public offering price for each ADS and accompanying Warrants is $0.81, which was the closing price of our ADSs on The Nasdaq
Capital Market on April 21, 2025.

The Pre-Funded Warrants sold in lieu of ADSs to those purchasers, who, together with their affiliates
and certain related parties, would beneficially own more than 4.99% (or at the election of the purchaser, 9.99%), will have an exercise price equal to the United States dollar equivalent of £0.01, based on the exchange rate on the date of
exercise. For each Pre-Funded Warrant that we sell, the number of ADSs offered will be decreased on a one-for-one basis.

Each Series A
Warrant will have an exercise price equal to 125% of the combined public offering price, is exercisable on the Initial Exercise Date, and will expire on the five-year anniversary of the Initial Exercise Date. The holders of the Series A Warrants
will be issued a maximum of 16,049,383 ADSs upon the cash exercise of the Series A Warrants.

3

Each Series B Warrant will have an exercise price equal to 125% of the combined public offering price, is exercisable on the Initial Exercise Date, and will expire on the two and one half-year anniversary of the Initial Exercise Date. A holder of Series B Warrants may, at any time after the eleventh trading day following the Initial Exercise Date and in its sole discretion, exercise its Series B Warrants in whole or in part through the “zero exercise price” option. Each Series B Warrant is initially exerciable for one ADS at an exercise price equal to 125% of the combined public offering price; however if the holder elects the “zero exercise price” option, the number of ADSs issuable upon exercise of each Series B Warrant would increase by three times the number of ADSs a holder would have received had the holder exercised for cash. As a result of